Development and validation of a method using ultra performance liquid chromatography coupled to tandem mass spectrometry for determination of zoledronic acid concentration in human bone

被引：12

作者：

Lo Faro, Alfredo Fabrizio ^{[1
]}

Giorgetti, Raffaele ^{[2
]}

Busardo, Francesco Paolo ^{[2
]}

Lodi, Giovanni ^{[1
]}

Martini, Valeria ^{[3
]}

Pispero, Alberto ^{[1
]}

Iriti, Marcello ^{[4
]}

Varoni, Elena Maria ^{[1
]}

机构：

[1] Univ Milan, Dipartimento Sci Biomed Chirurg & Odontoiatr, Milan, Italy

[2] Univ Politecn Marche, Sect Legal Med, Via Conca 71, Ancona, Italy

[3] UO Odontostomatol, Osped Papa Giovanni Bergamo 23, Bergamo, Italy

[4] Univ Milan, Dipartimento Sci Agr & Ambientali, Milan, Italy

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2019年 / 162卷

关键词：

Bisphosphonates; Osteonecrosis; Liquid chromatography; Mass spectrometry; HUMAN SERUM; IN-VITRO; BISPHOSPHONATES; PLASMA; URINE; HYDROXYAPATITE; OSTEONECROSIS; OSTEOPOROSIS; PHOSPHONATES; BIOLOGY;

D O I：

10.1016/j.jpba.2018.09.042

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

A method for the extraction and quantification of zoledronic acid (ZA) from human bone was set up and validated. This method allowed the quantification of ZA from jawbone sequestrations of patients affected by bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with ZA treatment. The analyte was extracted from the bone tissues with phosphoric acid and derivatized using trimethylsilyl diazomethane (TMS-DAM). ZA tetramethyl phosphonate was then quantified by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), showing high accuracy, repeatability and selectivity. Lower limits of quantification and detection (LLOQ and LLQD) were 3.4 ng/mL and 1 ng/mg, respectively. This study fully described the analytical process for the determination of ZA in human bone sequestrations, representing a pivotal step for further biomedical research on ZA and BRONJ. (C) 2018 Elsevier B.V. All rights reserved.

引用

页码：286 / 290

页数：5

共 23 条

[1] Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment [J].

Allen, Matthew R. .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (11) :1371-1378

[2] Advances in the biology and treatment of myeloma bone disease [J].

Berenson, JR .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (22) :S16-S20

[3] New advances in the biology and treatment of myeloma bone disease [J].

Berenson, JR .

SEMINARS IN HEMATOLOGY, 2001, 38 (02) :15-20

[4] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[5] A review of the clinical implications of bisphosphonates in dentistry [J].

Borromeo, G. L. ;

Tsao, C. E. ;

Darby, I. B. ;

Ebeling, P. R. .

AUSTRALIAN DENTAL JOURNAL, 2011, 56 (01) :2-9

[6] INHIBITORY EFFECT OF PHOSPHONATES ON FORMATION OF CALCIUM PHOSPHATE CRYSTALS IN-VITRO AND ON AORTIC AND KIDNEY CALCIFICATION IN-VIVO [J].

FLEISCH, HA ;

RUSSELL, RGG ;

BISAZ, S ;

MUHLBAUER, RC ;

WILLIAMS, DA .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1970, 1 (01) :12-+

[7]

Grewal Varinder S, 2008, N Y State Dent J, V74, P38

[8] Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients [J].

Hoff, Ana O. ;

Toth, Bela ;

Hu, Mimi ;

Hortobagyi, Gabriel N. ;

Gagel, Robert F. .

BISPHOSPHONATES AND OSTEONECROSIS OF THE JAW, 2011, 1218 :47-54

[9] Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine [J].

Legay, F ;

Gauron, S ;

Deckert, F ;

Gosset, G ;

Pfaar, U ;

Ravera, C ;

Wiegand, H ;

Schran, H .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (04) :897-911

[10] Development of superior bone scintigraphic agent from a series of 99mTc-labeled zoledronic acid derivatives [J].

Lin, Jianguo ;

Qiu, Ling ;

Cheng, Wen ;

Luo, Shineng ;

Xue, Li ;

Zhang, Shu .

APPLIED RADIATION AND ISOTOPES, 2012, 70 (05) :848-855

← 1 2 3 →